EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Microphysiological Systems Integrating Bioprinting, Organoids, Organ‐on‐a‐Chip, and AI: Next Generation Platforms for Pharmaceutical Development

Lei Xiu, Juan Zhang, Wooseung Bong, Seojune Jeong, Tao Yue iD, Sung Yun Hann iD, Yue Wang iD, Haitao Cui, Lijie Grace Zhang iD

Small · 2026

DOI: 10.1002/smll.76030 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Small, 2026. Verfasst von Lei Xiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioengineering, Chongqing University, Chongqing, China. Hauptthemen laut MEDLINE: Microphysiological Systems, Organoids, Bioprinting, Artificial Intelligence. Die Arbeit nennt 252 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chongqing Postgraduate Scientific Research Innovation Project, Chongqing University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microphysiological systems (MPS) have emerged as transformative in vitro platforms to address the long‐standing bottlenecks of conventional preclinical models, including poor physiological relevance inherent to 2D cultures, as well as species incompatibility and ethical constraints associated with animal models, thereby improving clinical predictability and redefining modern pharmaceutical development. This review highlights the innovative convergence of bioprinting, organoids, organ‐on‐a‐chip (OoC), and artificial intelligence (AI) as a next‐generation MPS framework, enabling precision reconstruction of human tissue microenvironments with unprecedented fidelity. Bioprinting delivers spatially defined 3D architectures; organoids recapitulate organ‐specific heterogeneity; OoC integrates dynamic physiological cues; and AI enables intelligent fabrication optimization, real‐time monitoring, and predictive drug‐response modeling. Their synergistic integration overcomes the inherent limitations of single‐technology systems. We emphasize state‐of‐the‐art MPS applications in disease‐drug screening, and toxicological assessment across tissues and multiorgan crosstalk models, underscoring their paradigm‐shifting potential. Remaining challenges, such as long‐term functional maturation, vascularization complexity, and standardized validation, and future directions, including multi‐cue integration, modular scalability, and AI‐driven in vitro‐in vivo correlation, are concisely outlined. This interdisciplinary synthesis establishes MPS as a cornerstone technology to accelerate pharmaceutical innovation, reduce reliance on animal models, and advance precision medicine toward clinical translation, thereby filling a critical gap in current biomedical research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Microphysiological SystemsOrganoidsBioprintingArtificial IntelligenceDrug DevelopmentLab-On-A-Chip DevicesHumansAnimals

Stichwörter der Autor:innen

artificial intelligencebioprintingmicrophysiological systemsorganoidsorgan‐on‐a‐chip

Autor:innen und Institutionen

  • College of Bioengineering, Chongqing University, Chongqing, China.
  • Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, Chongqing, China.
  • School of Future Technology, Shanghai University, Shanghai, China.
  • Department of Precision Mechanical Engineering, Kyungpook National University, Sangju, South Korea.
  • School of Mechatronics Engineering and Automation, Shanghai University, Shanghai, China.
  • Convergence Research Center of Mechanical and Chemical Engineering (CRCMCE), Kyungpook National University, Sangju, South Korea.

ORCID-Profile: Tao Yue, Sung Yun Hann, Yue Wang, Lijie Grace Zhang

Förderung

  • National Natural Science Foundation of China
  • Chongqing Postgraduate Scientific Research Innovation Project
  • Chongqing University
  • Gyeongbuk ANCHOR CENTER
  • Ministry of Education
  • National Research Foundation of Korea

Zitieren

APA

Xiu, L., Zhang, J., Bong, W., Jeong, S., Yue, T., Hann, S. Y., Wang, Y., Cui, H., & Zhang, L. G. (2026). Microphysiological Systems Integrating Bioprinting, Organoids, Organ‐on‐a‐Chip, and AI: Next Generation Platforms for Pharmaceutical Development. Small. https://doi.org/10.1002/smll.76030

Vancouver

Xiu L, Zhang J, Bong W, Jeong S, Yue T, Hann SY, et al. Microphysiological Systems Integrating Bioprinting, Organoids, Organ‐on‐a‐Chip, and AI: Next Generation Platforms for Pharmaceutical Development. Small. 2026. doi:10.1002/smll.76030

BibTeX
@article{Xiu2026,
  author = {Xiu, Lei and Zhang, Juan and Bong, Wooseung and Jeong, Seojune and Yue, Tao and Hann, Sung Yun and Wang, Yue and Cui, Haitao and Zhang, Lijie Grace},
  title = {Microphysiological Systems Integrating Bioprinting, Organoids, Organ‐on‐a‐Chip, and AI: Next Generation Platforms for Pharmaceutical Development},
  journal = {Small},
  year = {2026},
  doi = {10.1002/smll.76030}
}
Kostenlos starten →